NCT01471171 - Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

112

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Aclidinium Bromide

1 puff of 400 micro grams in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)

DRUG

Placebo

1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h)

Trial Locations (14)

Almirall Investigational Site #10, Berlin

Almirall Investigational Site #6, Berlin

Almirall Investigational Site #2, Berlin

Almirall Investigational Site #8, Hamburg

Almirall Investigational Site #9, Hamburg

Almirall Investigational Site #5, Großhansdorf

Almirall Investigational Site #7, Lübeck

Almirall Investigational Site #2, Madrid

Almirall Investigational Site #3, Hanover

Almirall Investigational Site #4, Frankfurt

Almirall Investigational Site #1, Wiesbaden

Almirall Investigational Site #1, Alicante

Almirall Investigational Site #4, Barcelona

Almirall Investigational Site #2, London